biOasis Announces Acquisition of Intellectual Property
News Aug 10, 2011
biOasis Technologies Inc. has announced that its wholly owned subsidiary biOasis Advanced Technologies Inc. has entered into a worldwide assignment (the "Assignment") to acquire certain Intellectual Property.
Pursuant to the Assignment, the Company will pay $25,000 in cash and will issue 350,000 warrants at an exercise price of $0.575 and 100,000 warrants at an exercise price of $0.50.
Each warrant is exercisable into one common share of the Company for a period of five years from the date of issuance.
In the event that a patent with respect to the intellectual property is issued to biOasis Advanced Technologies Inc. in either Europe or the United States of America, the Company will grant a further 300,000 warrants.
These further warrants shall be priced at the closing share price of the Company on the date of the issuance of such patent and in any case not less than $0.50 and shall be exercisable into one common share of the Company for a period of two years from date of grant.
The acquisition will be subject to certain conditions including TSX Venture Exchange approval.
When the Human Genome Project was completed, in 2003, it opened the door to a radical new idea of health - that of personalized medicine, in which disease risk and appropriate treatment would be gleaned from one's genetic makeup. In a new article, researchers discuss how gene interaction networks hold the clues to disease susceptibility and treatment response.READ MORE
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative diseases in human brain tissue samples, including Alzheimer’s disease and chronic traumatic encephalopathy. Their discovery will help scientists develop targeted biomarkers and therapeutics, resulting in a more accurate diagnosis of complex brain diseases.READ MORE